Photo by lazyartistgallery from unsplash
Circulating tumor DNA (ctDNA) may be a useful biomarker for minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer-and MRD may be a good predictor of relapse.… Click to show full abstract
Circulating tumor DNA (ctDNA) may be a useful biomarker for minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer-and MRD may be a good predictor of relapse. In the TRACERx study, a ctDNA assay confirmed MRD negativity in more than 99% of patients-and detected MRD in patients who relapsed before their disease was picked up by standard imaging.
Keywords:
mrd may;
predict relapse;
mrd;
may predict;
relapse nsclc
Journal Title: Cancer discovery
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!